编号 |
产品名称 |
CAS号 |
规格 |
价格 |
|
| 1708015 |
D-缬更昔洛韦
D-Valganciclovir (10 mg) (2-[(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)-methoxy]-3-hydroxypropyl D-valine ester monohydrochloride) |
N/A |
|
|
| 1708503 |
L-缬氨酸
L-Valine (200 mg) |
72-18-4 |
|
|
| 1708707 |
丙戊酸
Valproic Acid (500 mg) |
99-66-1 |
|
|
| 1708718 |
丙戊酸USP杂质B
Valproic Acid Related Compound B (25 mg) ((2RS)-2-(1-methylethyl)pentanoic acid) |
62391-99-5 |
|
|
| 1708729 |
丙戊酸USP杂质A
Valproic Acid Related Compound A (0.25 mL) (diallyl acetic acid) |
99-67-2 |
|
|
| 1708730 |
戊柔比星
Valrubicin (100 mg) |
56124-62-0 |
|
|
| 1708751 |
戊柔比星分辨率混合标准品
Valrubicin Resolution Mixture (25 mg) (valrubicin spiked with seven related substances) |
N/A |
|
|
| 1708762 |
缬沙坦
Valsartan (350 mg) |
137862-53-4 |
|
|
| 1708773 |
缬沙坦USP杂质A
Valsartan Related Compound A (10 mg) ((R)-N-Valeryl-N-([2’-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl)-valine) |
137862-87-4 |
|
|
| 1708784 |
缬沙坦USP杂质B
Valsartan Related Compound B (10 mg) (N-butyryl-N-{[2’-(1H-tetrazole-5-yl)-biphenyl-4-yl]methyl}-L-valine) |
N/A |
|
|
| 1708795 |
缬沙坦USP杂质C
Valsartan Related Compound C (10 mg) (N-valeryl-N-{[2’-(1H-tetrazole-5-yl)biphenyl-4-yl]methyl}-L-valine benzyl ester) |
137863-20-8 |
|
|
| 1709007 |
盐酸万古霉素
Vancomycin Hydrochloride (4 vials, each vial contains 99,300 mcg of vancomycin activity) |
1404-93-9 |
|
|
| 1709018 |
万古霉素B(含单二氯万古霉素)
Vancomycin B with Monodechlorovancomycin (300 mg) |
N/A |
|
|
| 1710006 |
香兰素
Vanillin (200 mg) |
121-33-5 |
|
|
| 1711009 |
香兰素熔点标准品
Vanillin Melting Point Standard (1 g) (Approximately 82 degrees) |
121-33-5 |
|
|
| 1711031 |
骆驼蓬碱
Vasicine (20 mg) |
6159-55-3 |
|
|
| 1711100 |
精氨酸加压素
Vasopressin (1.70 mg) (8-L-arginine vasopressin) (COLD SHIPMENT REQUIRED) |
113-79-1 |
|
|
| 1711133 |
赖氨加压素
Lypressin (2.2 mg) (8-L-lysine vasopressin) (COLD SHIPMENT REQUIRED) |
50-57-7 |
|
|
| 1711155 |
维库溴铵
Vecuronium Bromide (50 mg) |
50700-72-6 |
|
|
| 1711166 |
Vecuronium Bromide Related Compound A (25 mg) (3alpha, 17beta-diacetyl-oxy-2beta, 16beta-bispiperidinyl-5alpha-androstan) |
N/A |
|
|
